Desai, Nihar R.
Inzucchi, Silvio E.
Wright, Eugene E. Jr.
Funding for this research was provided by:
Boehringer Ingelheim
Eli Lilly and Company
Article History
Received: 11 July 2025
Accepted: 23 February 2026
First Online: 15 April 2026
Declarations
:
: Nihar R. Desai: reports research grants and consulting for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, SCPharmaceuticals, and Vifor. Silvio E. Inzucchi: has served as a consultant or on clinical trial committees or advisory boards for Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Merck, Pfizer, Corcept, and Bayer; and has delivered lectures sponsored by AstraZeneca and Boehringer Ingelheim. Eugene E. Wright Jr: has participated in speaker bureaus for Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Eli Lilly, and Sanofi. He has served as a consultant/advisory board member for: Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Eli Lilly, Embecta, Medtronic, and Sanofi. He also reports honorarium and writing support from Springer Health; advisor for Ascensia; content reviewer for UpToDate; and Clinical Diabetes Associate Editor for American Diabetes Association Publications.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.